Sanofi Signs US$2.26 B Deal with Start-Up DiCE Molecules to Develop Next-Generation Oral Therapeutics

By Heather Cartwright & Natasha Berry

Pharma Deals Review: Vol 2016 Issue 4 (Table of Contents)

Published: 13 Apr-2016

DOI: 10.3833/pdr.v2016.i4.2152     ISSN: 1756-7874

Section: Research & Development

Fulltext:

Abstract

Continuing its strategy of investing in early-stage start-ups as part of its Sunrise Initiative, Sanofi has entered into a 5-year collaboration with Stanford University spin-out DiCE Molecules to discover potential new oral therapies for up to 12 targets spanning disease areas of strategic interest to Sanofi...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

PharmaDeals has now moved to a new platform (https://analyticslink.customerportal.iqvia.com). The current PharmaDeals website will be disabled from October 31, 2026. Please update your bookmarks and, if you have any issues accessing the new platform, please contact your IQVIA account manager.

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details